ClearPoint Neuro, Inc. (NASDAQ:CLPT – Get Free Report) saw a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 855,900 shares, a decrease of 37.5% from the June 30th total of 1,370,000 shares. Based on an average daily volume of 207,100 shares, the days-to-cover ratio is currently 4.1 days.
ClearPoint Neuro Stock Down 1.3 %
Shares of CLPT traded down $0.10 during midday trading on Friday, reaching $7.46. The company had a trading volume of 29,897 shares, compared to its average volume of 173,959. The firm has a 50 day simple moving average of $6.08 and a 200-day simple moving average of $6.43. The stock has a market cap of $204.55 million, a PE ratio of -8.77 and a beta of 1.07. ClearPoint Neuro has a 1-year low of $4.05 and a 1-year high of $7.97.
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The business had revenue of $7.64 million during the quarter, compared to analysts’ expectations of $7.04 million. ClearPoint Neuro had a negative net margin of 78.84% and a negative return on equity of 76.92%. As a group, sell-side analysts anticipate that ClearPoint Neuro will post -0.63 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ClearPoint Neuro
Analyst Upgrades and Downgrades
Separately, B. Riley started coverage on ClearPoint Neuro in a research note on Thursday. They issued a “buy” rating and a $10.00 target price on the stock.
Read Our Latest Research Report on CLPT
About ClearPoint Neuro
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Further Reading
- Five stocks we like better than ClearPoint Neuro
- Dividend Capture Strategy: What You Need to Know
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Market Sectors: What Are They and How Many Are There?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Golden Cross Stocks: Pattern, Examples and Charts
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.